ReviewRheumatology international2010
Perioperative management of immunosuppression in rheumatic diseases--what to do?
Review in Rheumatology international, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- [Recommendations of the German Society for Rheumatology on the perioperative approach under therapy with DMARDs and biologicals in inflammatory rheumatic diseases].Zeitschrift fur Rheumatologie · 2014Guideline
- Higher postoperative complication rates in patients with systemic lupus erythematosus undergoing surgical and obstetric procedures: a nationwide retrospective matched cohort study.Rheumatology international · 2026Article
- The Association Between Comorbidities and Medical Complications for Adult Spinal Deformity Surgery: What Factors Have the Greatest Impact on Adverse Events and Outcomes?Global spine journal · 2025Article
- Perioperative Considerations for Hip Arthroplasty in Patients with Rheumatoid Arthritis.Hip & pelvis · 2024Review
- Perioperative Management of Immunosuppressive Medications in Rheumatic Disease Patients Undergoing Arthroscopy.Current reviews in musculoskeletal medicine · 2021Review
- Acute surgical site infection after total knee arthroplasty in patients with rheumatoid arthritis versus osteoarthritis.Scientific reports · 2021Article
- Perioperative management of drugs commonly used in patients with rheumatic diseases: a review.Clinics (Sao Paulo, Brazil) · 2017Review
- Rheumatoid arthritis vs osteoarthritis in patients receiving total knee arthroplasty: perioperative outcomes.The Journal of arthroplasty · 2014Article
- Perioperative management of patients with rheumatic diseases.The open rheumatology journal · 2013Article
- [Rheumatic patients in the intensive care unit].Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2012Review
- Management of rheumatoid arthritis in the perioperative period.Canadian journal of surgery. Journal canadien de chirurgie · 2011Article
- Practical Guidance in Perioperative Management of Immunosuppressive Therapy for Rheumatology Patients Undergoing Elective Surgery.The Canadian journal of hospital pharmacyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To stop or not to stop immunosuppressive therapy in the perioperative setting puts the clinician to a challenge. The risk of potential wound infection with possible septic or even lethal consequences needs to be weighted against exacerbation of the rheumatic disease. However, exacerbation of autoimmune inflammatory activity needs to be treated with increasing immunosuppressive medication, thus leading to enhanced risk of local and systemic infection as well. Unfortunately, up to now there is no data from randomized, double-blind controlled clinical trials available on how to steer immunosuppressive therapy in the perioperative setting, making evidence-based recommendations difficult. Neither is there good evidence, if the risk of infectious complications under immunosuppressive therapy differs according to the type and localization of surgery performed. Finally, immunosuppressive co-medication, like glucocorticoid dosage, is not adequately addressed in the available studies, making interpretation of these studies even more problematic. Therefore, a decision has to be made on an individual basis. We discuss the available data on DMARD and biologics therapy in the perioperative setting and describe our own perioperative management with different DMARDs and biologics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.